Pediatric Foreign Body Ingestion

Pediatric Foreign Body Ingestion: Clinical Assessment, Triage, and Management

Based on the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Position Paper

---

1. Overview and Clinical Framework

• Source reference: European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Position Paper (literature review through June 2025).
• Clinical objective: Provide practical, evidence-informed guidance to differentiate foreign body (FB) ingestions requiring emergent intervention, urgent endoscopy, or safe watchful waiting.
• Multidisciplinary scope: Translates gastroenterology and emergency medicine consensus into actionable bedside algorithms.
• Evidence profile: Grounded in observational cohort studies, case series, and expert consensus where randomized clinical trials are ethically or practically unfeasible.

2. Four Core Assessment Factors

Every pediatric presentation must be evaluated across four primary clinical dimensions:

• Object type: Shape, size, sharpness, chemical composition, electrical activity (batteries), magnetism, and expansion potential (superabsorbent polymers).
• Anatomic location: Esophagus, stomach, or post-pyloric small/large bowel (verified by multi-view radiography when radiopaque).
• Clinical symptoms: Presence of airway compromise, drooling, dysphagia, odynophagia, chest pain, abdominal tenderness, fever, vomiting, or gastrointestinal bleeding.
• Time elapsed since ingestion: Duration of mucosal contact, battery discharge progression, or polymer expansion window.

3. Triage Categories and Timing of Removal

• Emergent removal (within 2 hours):
  • Esophageal button batteries (immediate risk of caustic liquefactive necrosis and vascular perforation).
  • Multiple magnets or magnet plus ferromagnetic metallic object (risk of bowel wall entrapment, pressure necrosis, perforation, and fistula).
  • Sharp, pointed foreign bodies lodged in the esophagus.
  • Complete esophageal obstruction (inability to handle oral secretions, risk of aspiration).
  • Any foreign body causing airway compromise or signs of systemic distress / visceral perforation.
• Urgent removal (within 24 hours):
  • Most symptomatic foreign bodies located in the esophagus or stomach without immediate airway compromise.
  • Asymptomatic esophageal blunt foreign bodies (e.g., coins retained for over 24 hours or unknown duration).
  • Sharp, pointed objects lodged in the stomach or proximal duodenum accessible by endoscope.
  • Gastric button batteries in children younger than 5 years if battery diameter exceeds 20 mm, or if patient becomes symptomatic.
• Watchful waiting / Observation:
  • Asymptomatic, benign, blunt foreign bodies (e.g., small coins, smooth toys) located in the stomach or past the pylorus.
  • Serial clinical evaluation with explicit return precautions; reflexive GI consultation is not indicated for low-risk gastric objects.

4. Anatomic Algorithms: Esophageal, Gastric, and Post-Pyloric Management

• Esophageal foreign bodies:
  • Highest complication rate due to thin esophageal wall and proximity to major vascular structures (aorta).
  • True impaction requires endoscopic retrieval; watchful waiting is restricted to brief observation (under 24 hours) for smooth blunt objects in completely asymptomatic patients.
• Gastric foreign bodies:
  • Most smooth objects pass spontaneously through the pylorus within 4 to 6 days.
  • Inpatient observation or outpatient follow-up with stool inspection is standard for benign objects.
  • Intervention indicated if objects fail to pass stomach after 2 to 4 weeks, or if symptoms develop.
• Post-pyloric foreign bodies:
  • Objects beyond the ligament of Treitz generally traverse the remainder of the gastrointestinal tract uneventfully.
  • Outpatient tracking with normal diet and stool monitoring.
  • Surgical evaluation required only if bowel obstruction, persistent localization at the ileocecal valve, peritonitis, or magnetic entrapment occurs.

5. Special Ingestion Scenarios and Clinical Pitfalls

• Button battery mitigation strategies (pre-hospital and pre-endoscopy):
  • Administer honey or sucralfate suspension immediately while arranging emergent endoscopy.
  • Honey dosing: 10 mL (2 teaspoons) every 10 minutes, up to 6 doses (only in children older than 1 year).
  • Sucralfate dosing: 10 mL (1 g) every 10 minutes, up to 3 doses.
  • Mechanism: Acts as a physical barrier and weak acid neutralizer, slowing tissue hydrolysis and caustic liquefactive necrosis.
  • Contraindications: Do not delay transport or endoscopy; do not administer honey to infants under 12 months (infantile botulism risk); do not use if perforation is suspected.
• Superabsorbent polymers (water beads):
  • Found in toys, sensory kits, and diapers.
  • Radiographically radiolucent; expand progressively by absorbing bowel fluid.
  • Cause delayed small bowel obstruction, intussusception, or perforation; maintain high clinical suspicion and low threshold for cross-sectional imaging (ultrasound or CT).
• Esophageal food bolus impaction:
  • Endoscopic disimpaction is definitive treatment.
  • Pharmacologic warning: Glucagon is not recommended due to lack of demonstrated clinical efficacy and high rate of adverse effects (retching, vomiting, secondary perforation risk).
• Toxic substance ingestions:
  • Differentiate caustic chemical burns (acids, alkalis) from inert foreign bodies.
  • Avoid gastric lavage, emetics, or blind blind-passage maneuvers.

6. Post-Removal Care and ED Bounceback Vigilance

• Discharge safety profile:
  • Thorough mucosal inspection post-retrieval to document ulceration depth or circumferential injury.
  • Patients with mucosal erosion require scheduled acid suppression (e.g., PPI therapy) and strict dietary advancement instructions.
• High-risk bounceback complications:
  • Delayed aorto-esophageal fistula formation: Can manifest days to weeks after button battery extraction.
  • "Sentinel bleed": Any minor hematemesis or melena in a post-battery extraction patient must be treated as a catastrophic impending rupture requiring emergent cardiothoracic/GI/vascular involvement.
  • Secondary esophageal stricture or mediastinitis: Monitor for progressive dysphagia, low-grade fevers, or neck/chest pain.

7. Key Clinical Practice Takeaways

• Know the 2-hour window: Esophageal button batteries, multiple magnets, and sharp esophageal objects require immediate mobilization of endoscopy and anesthesia teams.
• Embrace watchful waiting: Asymptomatic children with benign gastric foreign bodies do not require reflexive specialist consultation or hospitalization.
• Deprecate ineffective medications: Do not administer glucagon for esophageal impactions.
• Use pre-endoscopy bridge therapy: Administer honey or sucralfate for known or suspected button battery ingestion while mobilizing endoscopy.

Serum Uric Acid in the Diagnosis of Gout

Serum Uric Acid in the Diagnosis of Gout: Bedside Clinical Lecture Notes

Overview and Diagnostic Limitations

• Not a Standalone Diagnostic Test:
  • Serum uric acid (SUA) alone cannot confirm or exclude an acute gout flare.
  • Asymptomatic hyperuricemia is common (>20% of men, 4% of women), and the vast majority of hyperuricemic individuals never develop clinical gout.
• Acute Flare Dynamics and Diagnostic Pitfalls:
  • SUA levels frequently drop into the normal reference range during an acute attack.
  • The systemic acute-phase inflammatory response triggers increased renal clearance of uric acid.
  • A normal SUA level obtained during an acute flare carries low negative predictive value and does not rule out gout.

Gold Standard Diagnostic Method

• Synovial Fluid Arthrocentesis:
  • Direct examination under compensated polarized light microscopy demonstrating intracellular, needle-shaped, negatively birefringent monosodium urate (MSU) crystals remains definitive.
  • Joint fluid aspiration is also essential to rule out concurrent septic arthritis or pseudogout (calcium pyrophosphate crystal deposition).

Clinical Decision-Making and Prediction Tools

• Integrated Multimodal Assessment:
  • SUA must be interpreted strictly as one component of a comprehensive clinical evaluation.
• Janssens Clinical Prediction Rule:
  • Validated scoring system for acute gout when joint aspiration is unfeasible:
  • Male sex (1 point)
  • Prior patient-reported gout attack (1 point)
  • Rapid symptom onset within 1 day (1 point)
  • Joint erythema and redness (1 point)
  • First metatarsophalangeal (MTP) joint involvement (1 point)
  • Hypertension or cardiovascular disease history (1 point)
  • Elevated serum uric acid level (1 point)
  • Interpretation: A score under 4 excludes acute gout in over 97% of patients.

Therapeutic Implications

• Long-Term Management vs. Acute Flare:
  • Reserve SUA primarily for guiding the initiation and titration of urate-lowering therapy (ULT, such as allopurinol or febuxostat) after the acute flare resolves.
  • Do not initiate urate-lowering drugs during an active presentation based solely on an isolated SUA measurement.

Summary Takeaways

• Aspirate joint fluid for crystal analysis whenever clinically feasible.
• A normal SUA does not exclude acute gout; an elevated SUA does not prove acute gout.
• Use validated predictive rules (such as the Janssens rule) when arthrocentesis is unavailable.
• Treat SUA as a longitudinal titration target, not as an acute diagnostic gold standard.

---

Reference: Dalbeth N et al. Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis. Ann Rheum Dis. 2018;77(7):1048-1052. doi:10.1136/annrheumdis-2017-212288.

Severe Agitation Management

Rapid Pharmacologic Control of Severe Adult Agitation in the Emergency Department

Clinical Lecture Notes

---

1. Initial Approach and Safety Principles

• Verbal de-escalation and environmental management:
  • Attempt non-pharmacologic verbal de-escalation, space optimization, and initial assessment as early baseline measures.
• Threshold for medication:
  • Do not delay parenteral medication when severe, violent agitation or imminent danger of physical harm to the patient or clinical staff prevents a safe physical evaluation.

2. Preferred First-Line Pharmacotherapy (ACEP Level B)

• Combination therapy (preferred for rapid, efficacious sedation):
  • Droperidol plus midazolam, or an atypical antipsychotic (such as olanzapine) plus midazolam.
  • Clinical rationale: Combination therapy achieves significantly faster sedation onset and superior efficacy compared to monotherapy regimens.
• First-line monotherapy alternatives:
  • Droperidol monotherapy or an atypical antipsychotic monotherapy is also reasonable when combination therapy is not selected.

3. Conventional and Alternative Regimens (ACEP Level B)

• Haloperidol-based therapy:
  • Haloperidol administered alone or in combination with lorazepam remains an evidence-supported alternative.
  • Particularly useful when first-line preferred agents (droperidol, parenteral atypicals) are unavailable on hospital formulary.
• Individualizing medication selection:
  • Tailor drug choices to suspected toxidromes, known past adverse medication responses, anticholinergic burden, and institutional sedation protocols.

4. Rescue Therapy for Imminently Dangerous Agitation (ACEP Level C)

• Role of intramuscular (IM) ketamine:
  • Indicated for immediately dangerous, unmanageable agitation where rapid, definitive control is critical to life safety.
  • Strength of recommendation: ACEP Level C recommendation based on lower-certainty evidence.
  • Clinical caveat: Ketamine is a specialized rescue agent; it is NOT recommended as routine first-line therapy for general agitation.

5. Post-Sedation Monitoring and Diagnostic Workup

• Resuscitative surveillance after parenteral sedation:
  • Implement continuous cardiorespiratory monitoring immediately following medication delivery.
  • Continuously assess oxygenation and adequacy of ventilation (pulse oximetry and capnography).
  • Ensure immediate bedside availability of bag-valve-mask, suction, and definitive advanced airway equipment.
• Secondary diagnostic assessment:
  • Once physical control is established, immediately re-evaluate the patient for underlying reversible medical drivers:
    • Occult physical or intracranial trauma.
    • Hypoglycemia (rapid point-of-care fingerstick).
    • Hypoxia and hypercapnia.
    • Toxidromes (sympathomimetic toxicity, anticholinergic syndrome, withdrawal).
    • Organic delirium, acute central nervous system infection, or sepsis.

6. Key Literature Sources

• American College of Emergency Physicians (ACEP): Clinical Policy: Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department With Acute Agitation. Annals of Emergency Medicine 2024;83:e1-e30 (PMID: 38105109, DOI: 10.1016/j.annemergmed.2023.09.010).
• Taylor et al.: Midazolam-Droperidol, Droperidol, or Olanzapine for Acute Agitation: A Randomised Clinical Trial. Annals of Emergency Medicine 2017;69:318-326.e1 (DOI: 10.1016/j.annemergmed.2016.07.033).

7. Summary Takeaway

When verbal de-escalation fails and imminent harm threatens safety, combination therapy (droperidol or an atypical antipsychotic plus midazolam) provides the fastest and most reliable sedation (ACEP Level B). Reserve IM ketamine for extreme, imminently life-threatening agitation where immediate cessation of violent motor activity is paramount (ACEP Level C). Every parenterally sedated patient requires dedicated cardiorespiratory and ventilatory monitoring, followed by an immediate secondary search for underlying medical and toxicologic etiologies.

---

Clinical Lecture Notes - Emergency Medicine and Behavioral Emergencies Reference

Convulsive Status Epilepticus

Time-Critical Treatment of Convulsive Status Epilepticus

Clinical Lecture Notes

---

1. Definition and Immediate Resuscitation (0 to 5 Minutes)

• Diagnostic threshold:
  • Any continuous generalized convulsive seizure lasting 5 minutes or longer, or two or more distinct seizures without full recovery of consciousness between episodes, must be treated as convulsive status epilepticus (CSE).
• Immediate stabilization priorities:
  • Airway, breathing, and circulation: maintain patent airway, deliver high-flow oxygen, and position to prevent aspiration.
  • Rapid point-of-care testing: check capillary blood glucose immediately to identify and correct hypoglycemia.
  • Vascular access: establish intravenous (IV) or intraosseous (IO) access rapidly.
  • Immediate pharmacology: administer an adequately dosed first-line benzodiazepine immediately without waiting for lab work or imaging.

2. Structured Time-Based Management Pathway

• Phase 1: First-line therapy (5 to 20 minutes):
  • Administer an initial full-dose benzodiazepine (such as IV lorazepam, IM midazolam, or IV diazepam).
  • If the seizure persists after an appropriate interval (typically 5 to 10 minutes), a single repeat dose of benzodiazepine may be given per protocol.
• Phase 2: Second-line therapy (20 to 40 minutes):
  • If convulsions continue despite adequate first-line dosing, immediately initiate a full weight-based loading dose of an established second-line antiseizure medication (ASM: levetiracetam, fosphenytoin, or sodium valproate).
  • Concurrent preparation principle: Prepare second-line ASMs at the bedside simultaneously while administering the benzodiazepine, rather than waiting sequentially for the benzodiazepine to fail.

3. Clinical Trial Evidence and Timing Benchmarks

• ESETT secondary analysis data (Zehtabchi et al., 2026):
  • Cohort: 487 patients aged 2 years and older with benzodiazepine-refractory status epilepticus.
  • Time benchmarks: Median ED arrival-to-benzodiazepine time was 11 minutes; median ED arrival-to-second-line ASM initiation was 26 minutes.
  • Clinical outcome: Earlier administration of second-line ASM was significantly associated with treatment success (p = 0.03).
  • Clinical implication: While causality is observational, minimizing door-to-second-line medication delivery time improves seizure termination rates.

4. Prehospital Rescue Therapy and Pediatric Action Plans

• Prehospital care gap:
  • Approximately half of all status epilepticus patients receive no rescue benzodiazepine prior to emergency department arrival.
• Pediatric seizure action plans (Vigevano et al., 2026):
  • Children with known epilepsy require an individualized seizure action plan empowering families and caregivers to deliver prompt rescue medication.
  • European pediatric consensus uses a 5-minute continuous seizure threshold for initiating rescue therapy.
  • Route preference: Buccal midazolam is preferred over rectal diazepam for infants older than 6 months due to superior ease of administration, social acceptability, and rapid mucosal absorption.

5. Critical Pitfalls and Safety Hazards

• Avoid serial underdosing:
  • The most frequent error in status epilepticus management is administering subtherapeutic benzodiazepine doses, which delays seizure cessation without protecting the airway.
• Avoid excessive repeat benzodiazepine dosing:
  • Giving multiple unprotocolized benzodiazepine boluses beyond two doses rarely terminates refractory seizures.
  • Stacking doses drastically increases the incidence of respiratory depression, hemodynamic instability, and unplanned intubation, while critically postponing definitive second-line ASM infusion.

6. Key Literature Sources

• Zehtabchi et al.: Academic Emergency Medicine 2026 (PMID: 41854499, DOI: 10.1111/acem.70265).
• Vigevano et al.: BMC Pediatrics 2026 (PMID: 41593567, DOI: 10.1186/s12887-026-06520-3).

7. Summary Takeaway

Treat convulsive seizures reaching 5 minutes as status epilepticus with weight-appropriate, full-dose benzodiazepines without waiting for laboratory results. Prepare second-line antiseizure medications concurrently at the bedside to ensure infusion begins by 20 minutes if seizures persist. Eliminate repeated subtherapeutic benzodiazepine cycles to prevent compounding respiratory depression and dangerous treatment delays.

---

Clinical Lecture Notes - Emergency Medicine and Pediatric Neurology Reference

Asymptomatic Elevated BP

Asymptomatic Elevated Blood Pressure in the Emergency Department

Clinical Lecture Notes

---

1. Diagnostic Differentiation: Emergency vs Asymptomatic Elevation

• Hypertensive emergency definition:
  • Defined strictly by the presence of acute, progressive target-organ damage, not by a specific blood pressure number alone.
  • Must evaluate systematically for acute clinical features:
    • Acute ischemic stroke or intracranial hemorrhage.
    • Acute coronary syndrome (ACS).
    • Acute decompensated heart failure and pulmonary edema.
    • Hypertensive encephalopathy.
    • Acute aortic syndromes (dissection, intramural hematoma).
    • Acute kidney injury (AKI).
    • Preeclampsia or eclampsia in pregnant or postpartum patients.
• Hypertensive emergency management:
  • Requires immediate ICU or monitored care with prompt, titratable intravenous antihypertensive therapy.
  • Specific blood pressure targets and the velocity of blood pressure lowering are dictated by the specific organ system injured.

2. Evaluation of Asymptomatic Elevated Blood Pressure

• Repeat measurement and confounding factors:
  • Re-measure blood pressure using an appropriately sized cuff and proper patient positioning after a period of rest.
  • Actively screen for and address reversible exacerbating factors: acute pain, emotional anxiety, missed home medications, white-coat effect, and measurement error.
  • A single elevated emergency department blood pressure measurement should never be used to establish a new formal diagnosis of chronic hypertension.
• Avoid acute blood pressure normalization:
  • Do not rapidly lower asymptomatic elevated blood pressure in the emergency department, particularly with intravenous agents.
  • Acute reduction offers no proven clinical benefit in asymptomatic patients.
  • Inpatient and observational evidence indicates clear signals of overtreatment harm, including cerebral, renal, and coronary hypoperfusion.
  • Available evidence is context-dependent and warrants a conservative, patient-centered approach.

3. Discharge Management and Outpatient Follow-Up

• Initiation of oral antihypertensive therapy:
  • Routine initiation in the ED is not required for all patients.
  • According to the ACEP 2025 Clinical Policy (Level C consensus recommendation), emergency clinicians may consider initiating oral antihypertensives at discharge when outpatient primary care follow-up is unreliable or healthcare access is significantly limited.
• Follow-up coordination:
  • Mandatory arrangement of timely outpatient follow-up for all patients discharged from the emergency department with asymptomatic elevated blood pressure.
  • Emphasize home blood pressure monitoring, outpatient titration, and primary care reassessment.

4. Key Literature and Guideline Sources

• American College of Emergency Physicians (ACEP): Clinical Policy: Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department With Asymptomatic Elevated Blood Pressure. Annals of Emergency Medicine 2025;86:e1-e11 (PMID: 40543987).
• American Heart Association (AHA): Scientific Statement: Management of Patients With Asymptomatic Elevated Blood Pressure in Healthcare Settings. Hypertension 2024;81:e94-e106 (DOI: 10.1161/HYP.0000000000000238).
• Degtyar et al.: Current Hypertension Reports 2025 (PMID: 40528102).

5. Summary Takeaway

Differentiate true hypertensive emergency (acute target-organ damage) from asymptomatic blood pressure elevation; treat the patient, not the monitor. Avoid acute intravenous antihypertensives for asymptomatic patients, as rapid lowering causes net harm through hypoperfusion. Focus on proper re-measurement, mitigating acute stressors, selective discharge prescribing when follow-up is compromised, and securing reliable outpatient follow-up.

---

Clinical Lecture Notes - Emergency Medicine and Cardiovascular Care Reference

Acute Pancreatitis Management

Acute Pancreatitis: Emergency Department Management

Clinical Lecture Notes

---

1. Clinical Presentation and Diagnostic Criteria

• Classic presentation:
  • Severe epigastric abdominal pain characteristically radiating to the back.
  • Associated with nausea, vomiting, and anorexia.
  • Pain characteristically improves with forward trunk flexion (sitting up and leaning forward).
• Diagnostic confirmation:
  • Serum lipase elevated to greater than 3 times the upper limit of normal.
  • Lipase demonstrates superior sensitivity and specificity compared to amylase; diagnostic sensitivity peaks at approximately 24 hours.
• Diagnostic imaging (contrast-enhanced CT abdomen/pelvis):
  • Not routinely required on initial presentation if clinical presentation and lipase criteria are met.
  • Indicated when diagnostic uncertainty exists or to exclude alternative intra-abdominal emergencies.
  • Optimal timing for detecting pancreatic necrosis or local complications is after 72 hours from symptom onset.

2. Initial Resuscitation and Fluid Therapy

• Goal-directed early fluid resuscitation:
  • Early resuscitation within the first 24 hours is paramount.
  • Administer isotonic crystalloids at 250 to 500 mL/hr; Lactated Ringer solution is preferred over normal saline.
• Resuscitation targets and safety monitoring:
  • Objective goal: Urine output greater than 0.5 mL/kg/hr, accompanied by normalization of heart rate and mean arterial pressure.
  • Exercise caution and monitor closely for volume overload, particularly in elderly patients or those with underlying cardiac or renal disease.
• Nutritional strategy:
  • Maintain NPO status during the acute hyperacute phase.
  • Early oral refeeding with a low-fat diet should be initiated promptly once abdominal pain resolves, ileus clears, and the patient tolerates oral fluids.

3. Risk Stratification and Prognostication

• Bedside Index of Severity in Acute Pancreatitis (BISAP) score:
  • Evaluated within the first 24 hours to predict in-hospital mortality.
  • Score components:
    • BUN greater than 25 mg/dL.
    • Impaired mental status (GCS less than 15).
    • Systemic Inflammatory Response Syndrome (SIRS criteria met).
    • Age greater than 60 years.
    • Pleural effusion present on chest radiography or CT.
  • Clinical interpretation: A BISAP score of 2 or higher indicates a significantly increased risk of severe disease and mortality.
• Dynamic risk marker:
  • Persistent SIRS lasting 48 hours or longer is a strong independent predictor of multiorgan failure and pancreatic necrosis.

4. Antibiotic Indications and Stewardship

• Sterile pancreatitis:
  • Prophylactic antibiotics are NOT recommended for acute pancreatitis or sterile peripancreatic necrosis.
• Infected necrosis:
  • Initiate broad-spectrum intravenous antibiotics (such as piperacillin-tazobactam or carbapenems) only when infected necrosis is suspected or confirmed.
  • Clinical triggers for suspected infection: persistent fever, progressive leukocytosis, clinical deterioration, or retroperitoneal gas bubbles demonstrated on CT.

5. Disposition and Level of Care

• Floor admission:
  • Appropriate for mild acute pancreatitis with resolving pain, normal vital signs, and BISAP score less than 2.
• Intensive Care Unit (ICU) / Step-down admission:
  • Mandatory for patients with BISAP score of 2 or higher.
  • Required for persistent organ failure (hypotension, respiratory failure, renal impairment) or high-risk medical comorbidities.

6. Summary Takeaway

Prompt early volume resuscitation with Lactated Ringer solution (250 to 500 mL/hr) during the first 24 hours improves outcomes, titrating against urine output and volume status. Avoid routine prophylactic antibiotics; reserve antimicrobial therapy strictly for proven or strongly suspected infected necrosis. Stratify early risk using the BISAP score and watch for persistent SIRS at 48 hours to guide timely ICU level disposition.

---

Clinical Lecture Notes - Emergency Medicine and Gastroenterology Reference

Treatment of Bell's Palsy

Clinical Lecture Notes

---

1. Corticosteroid Therapy (First-Line Standard of Care)

• Timing: Initiate oral corticosteroids within 72 hours of symptom onset to maximize facial nerve recovery.
• Population differences:
  • Adults: Significantly increases the rate and likelihood of complete facial nerve functional recovery.
  • Pediatric patients: Routine corticosteroids show no significant benefit, as the majority of children achieve complete spontaneous recovery without treatment.
• Standard adult dosing regimens:
  • Prednisolone 25 mg PO twice daily for 10 days, or
  • Prednisone / Prednisolone 60 mg PO daily for 5 days, followed by a 5-day taper over the subsequent 5 days.

2. Role of Antivirals

• Ineffective as monotherapy:
  • Antiviral monotherapy (acyclovir, valacyclovir, or famciclovir) is ineffective and should never be prescribed alone.
• Clinical utility of combination therapy (Steroids + Antivirals):
  • Across unselected populations, adding antivirals provides modest improvement in overall recovery rates.
  • Significantly reduces long-term sequelae, notably motor synkinesis, crocodile tears (gustatory lacrimation), and permanent residual deficit.
• Specific indications for adding antiviral therapy:
  • Severe initial paralysis: House-Brackmann grade V or VI presentation.
  • Intense otalgia or presentation suspicious for herpes zoster sine herpete.
  • Confirmed varicella-zoster virus (Ramsay Hunt syndrome; mandatory antiviral indication).
• Recommended combination regimen:
  • Famciclovir 750 mg PO daily for 7 days (or 250 mg PO TID for 7 days).
  • High-dose tapered corticosteroid: Prednisolone 80 mg PO daily tapered over 12 days (or 1 mg/kg/day in lower-weight adults).
  • Evidence profile: Network meta-analyses indicate famciclovir achieves a higher probability of recovery compared to other antiviral agents.

3. Eye Protection and Supportive Measures

• Prevention of exposure keratopathy:
  • Incomplete eyelid closure (lagophthalmos) risks corneal abrasion, ulceration, and permanent visual loss.
• Comprehensive corneal protection bundle:
  • Daytime: Frequent instillation of preservative-free lubricating artificial tears.
  • Bedtime: Preservative-free lubricating ophthalmic ointment.
  • Nighttime: Moisture-retaining eye chambers or protective shields, or careful taping of the upper eyelid closed.
• Adjunctive therapies:
  • Physical therapy to promote neuromuscular coordination during reinnervation.
  • Botulinum toxin injections for management of delayed motor synkinesis or severe resting asymmetry.

4. Specialist Referral and Red Flags

• Triggers for immediate otolaryngology (ENT) or neurology consultation:
  • Absence of clinical improvement after 3 months from onset.
  • Bilateral facial weakness (mandates evaluation for Lyme disease, Guillain-Barre syndrome, or sarcoidosis).
  • Recurrent episodes of facial paralysis.
• Long-term intervention:
  • Consideration of static or dynamic facial reanimation surgery for patients with persistent, disfiguring functional deficits.

5. Summary Takeaway

Oral corticosteroids initiated within 72 hours are the definitive first-line therapy for adult Bell's palsy. For patients with severe palsy (House-Brackmann grade V or VI) or zoster features, add famciclovir 750 mg daily for 7 days to high-dose tapered corticosteroids. Corneal protection via daytime tears, nighttime ointment, and nocturnal occlusion is mandatory for all patients with impaired eyelid closure.

---

Clinical Lecture Notes - Emergency and Acute Care Neurology Reference

Hydrocortisone in CAP

Hydrocortisone in Severe Community-Acquired Pneumonia (CAP)

Clinical Lecture Notes

---

Indications

• Target population: Adult patients hospitalized with severe bacterial CAP, typically managed in the ICU setting.
• Key clinical triggers:
  • Acute hypoxemic respiratory failure requiring advanced respiratory support: high-flow nasal cannula (HFNC), non-invasive ventilation (NIV), or invasive mechanical ventilation (IMV).
  • Septic shock requiring vasopressor support.
• Clinical guidelines (SCCM 2024):
  • Strong recommendation supporting corticosteroid use in severe bacterial CAP.
  • Routine use is not recommended for non-severe CAP or stable floor/ward patients.
• Important exclusions and caution:
  • Do not routinely extrapolate to influenza pneumonia or primary viral pneumonia.
  • Use extreme caution in patients with active fungal infections or severe baseline immunosuppression.

Dosing Regimens

• Standard dosage: Hydrocortisone 200 mg/day IV.
  • Administration modes: Continuous IV infusion (200 mg/day) or intermittent IV push (50 mg q6h).
  • Usual duration: 5 to 7 days based on clinical response; total dose should generally not exceed 400 mg/day.
• CAPE-COD trial protocol:
  • Induction: Hydrocortisone 200 mg/day IV for the first 4 days.
  • Responders (clinical improvement by Day 4): Taper down for an 8-day total course.
  • Non-responders (inadequate improvement by Day 4): Continue 200 mg/day through Day 7, followed by a taper for a 14-day total course.
• Key trial outcome:
  • 28-day all-cause mortality: 6.2% with hydrocortisone vs 11.9% with placebo.

Clinical Pearls and Monitoring

• Timing: Start early following ICU admission, concurrently with appropriate empiric antibiotic therapy, source control, and hemodynamic/respiratory stabilization.
• Overlap with septic shock: If septic shock is the dominant presentation, hydrocortisone 50 mg IV q6h fits standard stress-dose septic shock management; distinguish CAP response from shock reversal.
• Safety and monitoring:
  • Hyperglycemia: The most frequent adverse effect; requires routine blood glucose monitoring and glycemic control protocols.
  • Secondary infections: CAPE-COD demonstrated no statistically significant rise in hospital-acquired infections, but vigilance remains necessary.
  • Gastrointestinal bleeding: No significant increase in GI bleeding was observed in CAPE-COD; use standard ICU stress ulcer prophylaxis as indicated.
  • Neuromuscular weakness: Monitor for ICU-acquired weakness with extended courses.

Summary Takeaway

For severe bacterial CAP requiring ICU care, starting hydrocortisone at 200 mg/day IV for 5 to 7 days (with subsequent clinical response-guided tapering) provides an evidence-based, practical initial regimen.

---

Lecture Notes - Critical Care and Emergency Medicine Reference